To ensure a successful drug launch, biotech companies must start their commercialization planning at least 18 months in advance. This lead time is essential for deeply understanding the patient journey, identifying treatment barriers, and aligning clinical trials with outcomes that truly matter to patients and payers.

Rather than waiting for late-stage development, biotech startups should integrate commercial planning into early trials. This means building in data collection for payers, pricing, and patient access from the start. This "think with the end in mind" approach ensures the company has the right data for pivotal trials and market access.

Don't wait until Phase 3 to think about commercialization. Biotech firms must embed secondary endpoints in Phase 2 trials that capture quality of life and patient journey insights. This data is critical for building a compelling value proposition that resonates with payers and secures market access.

Successful drug launches require nailing three fundamentals. Common failures include: misjudging the patient population (epidemiology), failing to secure reimbursement and patient access, and lacking clear differentiation against the established "gold standard" treatment in physicians' minds.

True innovation in getting drugs to patients is not about pharma creating pricing models alone. It requires a multi-stakeholder partnership where payers, physicians, and manufacturers work together to solve problems for specific patient subgroups. This collaborative effort, not a unilateral one, is what truly saves lives and reduces costs.

While the FDA's primary endpoint for gout drugs is a simple biomarker (uric acid levels), Crystallis designed its Phase 3 trials around harder clinical endpoints like flare reduction. This forward-thinking strategy aims to generate data needed to convince payers of the drug's value, ensuring market access post-approval.

Biotech leaders must stop viewing commercialization as a post-approval task. The critical window is Phase 2 clinical trials. By embedding patient journey and quality of life insights into secondary endpoints, companies can build a compelling value proposition for payers and physicians. Waiting until Phase 3 is too late.

Acadia's R&D process starts by considering what will ultimately matter to patients, physicians, and payers. This "end in mind" approach ensures clinical trials are designed to demonstrate meaningful, commercially relevant benefits. It forces realism about a drug's potential impact early in development, avoiding wasted resources on therapies that won't be adopted.

Most drug launch failures stem from three core mistakes: engaging medical affairs too late to educate physicians pre-launch, having a flawed payer and reimbursement strategy, and neglecting to build a robust plan for generating and publishing real-world evidence to support the drug's value proposition.